Ann Rheum Dis 65:1521-1524 doi:10.1136/ard.2005.045484
  • Concise report

Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial

  1. N Putschky1,
  2. H-G Pott1,
  3. J G Kuipers2,
  4. H Zeidler3,
  5. M Hammer4,
  6. J Wollenhaupt5
  1. 1Rheumatologikum Hannover, Hannover, Germany
  2. 2Division of Rheumatology, Red Cross Hospital, Bremen, Germany
  3. 3Division of Rheumatology, Medical School Hannover, Hannover, Germany
  4. 4Division of Rheumatology, St Josef-Stift, Sendenhorst, Germany
  5. 5Division of Rheumatology, General Hospital Eilbeck, Hamburg, Germany
  1. Correspondence to:
    N Putschky
    Rheumatologikum Hannover, Rathenaustr 13/14, 30159 Hannover, Germany; service{at}
  • Accepted 10 April 2006


Objective: To compare the efficacy of a 10-day and a 4-month doxycylcine course for the treatment of Chlamydia trachomatis-reactive arthritis (Ct-ReA).

Methods: Patients with active Ct-ReA were enrolled in a prospective, multicentre, double-blind, controlled clinical trial and randomised to receive doxycycline 100 mg twice daily for 10 days followed either by placebo or by continued doxycycline 100 mg twice daily over 4 months. Various clinical and laboratory parameters referring to disease activity were recorded in the beginning and at the end of treatment.

Results: 32 of 37 patients included (15 men and 17 women; mean (standard deviation) disease duration 17 (13) months completed the study; 17 were randomised to short-term doxycycline and placebo (placebo group) and 15 to prolonged treatment with doxycycline (doxycycline group) over the 4-month study period. After this time, only two patients from each group went into remission. There were no drop-outs owing to adverse events or treatment failures.

Conclusions: The results of this study suggest that prolonged treatment with a 4-month course of doxycycline is not superior to short-term treatment over 10 days in patients with Ct-ReA.


  • Competing interests: None declared.